Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $211,000.

  • Silence Therapeutics' Capital Expenditures fell 95.31% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $117,000, marking a year-over-year change of. This contributed to the annual value of $211,000 for FY2024, which is 276.79% up from last year.
  • As of FY2024, Silence Therapeutics' Capital Expenditures stood at $211,000, which was up 276.79% from $56,000 recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Capital Expenditures peaked at $1.8 million during FY2021, and registered a low of $56,000 during FY2023.
  • In the last 3 years, Silence Therapeutics' Capital Expenditures had a median value of $173,000 in 2022 and averaged $146,667.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 5,610.27% in 2020, then crashed by 90.41% in 2022.
  • Silence Therapeutics' Capital Expenditures (Yearly) stood at $656,199 in 2020, then spiked by 174.88% to $1.8 million in 2021, then slumped by 90.41% to $173,000 in 2022, then slumped by 67.63% to $56,000 in 2023, then surged by 276.79% to $211,000 in 2024.